US Bancorp DE Has $130,000 Position in Vericel Co. (NASDAQ:VCEL)

US Bancorp DE reduced its holdings in Vericel Co. (NASDAQ:VCEL) by 22.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,365 shares of the biotechnology company’s stock after selling 704 shares during the period. US Bancorp DE’s holdings in Vericel were worth $130,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of VCEL. Arcadia Investment Management Corp MI bought a new stake in Vericel in the fourth quarter valued at approximately $48,000. Meeder Asset Management Inc. bought a new stake in Vericel in the third quarter valued at approximately $92,000. Geneos Wealth Management Inc. increased its stake in Vericel by 826.6% in the fourth quarter. Geneos Wealth Management Inc. now owns 2,511 shares of the biotechnology company’s stock valued at $138,000 after purchasing an additional 2,240 shares in the last quarter. KBC Group NV increased its stake in Vericel by 82.5% in the fourth quarter. KBC Group NV now owns 2,707 shares of the biotechnology company’s stock valued at $149,000 after purchasing an additional 1,224 shares in the last quarter. Finally, Quantbot Technologies LP bought a new stake in Vericel in the third quarter valued at approximately $146,000.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. BTIG Research upped their target price on shares of Vericel from $56.00 to $66.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. Stephens reaffirmed an “overweight” rating and issued a $65.00 target price on shares of Vericel in a research note on Wednesday, January 15th. Truist Financial reissued a “buy” rating and set a $61.00 price objective (down previously from $67.00) on shares of Vericel in a research report on Monday, March 3rd. StockNews.com raised shares of Vericel from a “sell” rating to a “hold” rating in a research report on Saturday, March 8th. Finally, HC Wainwright reissued a “buy” rating and set a $60.00 price objective on shares of Vericel in a research report on Friday, February 28th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Vericel currently has an average rating of “Moderate Buy” and a consensus price target of $62.29.

Vericel Trading Down 0.0 %

Vericel stock opened at $45.38 on Monday. The company has a market cap of $2.27 billion, a P/E ratio of 756.46 and a beta of 1.78. Vericel Co. has a 1-year low of $39.12 and a 1-year high of $63.00. The company has a fifty day simple moving average of $55.59 and a 200 day simple moving average of $51.84.

Insider Activity at Vericel

In related news, Director Robert L. Md Zerbe sold 2,500 shares of the firm’s stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $62.50, for a total value of $156,250.00. Following the completion of the transaction, the director now owns 26,595 shares of the company’s stock, valued at approximately $1,662,187.50. This trade represents a 8.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jonathan Siegal sold 1,092 shares of the firm’s stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $61.99, for a total transaction of $67,693.08. Following the completion of the transaction, the insider now directly owns 1,206 shares of the company’s stock, valued at approximately $74,759.94. This trade represents a 47.52 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 34,092 shares of company stock valued at $1,683,582. Corporate insiders own 7.20% of the company’s stock.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.